Across
- 4. VANISH: 67% of patients on BREXAFEMME at day 25
- 5. VANISH: Occurred on Day 11
- 8. CANDLE: Test completed to confirm VVC recurrence
- 11. Oral Prescription azole for VVC
- 12. OTC azole supplied as vaginal suppository
- 15. Oral azole approved for RVVC only
- 17. BREXAFEMME is contraindicated during this
Down
- 1. Number of BREXAFEMME tablets in daily dose
- 2. Increasing rates observed with widespread use of fluconazole
- 3. VANISH:BREXAFEMME demonstrated complete _ at day 10
- 6. 3+ infections in a year
- 7. VANISH: Based on patient-recorded symptom diaries
- 9. Azole MOA blocks this
- 10. May be associated with itching, burning, and messiness
- 13. Most common non-albicans Candida
- 14. CANDLE: Occurred on week 24
- 16. Blocked by BREXAFEMME